Perimenopause — the transitional years before menopause — can bring a cocktail of symptoms ranging from sleep disruption and brain fog to anxiety and hormonal chaos. For women in their late 30s and 40s who are often at the peak of their careers and juggling family responsibilities, it's not exactly a minor inconvenience. And yet the medical establishment has historically treated it like a footnote.

SF women are increasingly seeking out hormone replacement therapy (HRT) and other treatment options, but the experience of finding a knowledgeable, supportive provider in the city remains frustratingly hit-or-miss. Some women report being dismissed by doctors who chalk symptoms up to stress or aging. Others have found practitioners who actually listen — but only after a long and expensive search.

So why does this matter to a publication that usually talks about budgets and bad policy? Because this is fundamentally a market failure enabled by institutional inertia. When the medical system fails to adequately address the health needs of half its customers, that's not just a personal problem — it's an economic one. Lost productivity, unnecessary ER visits, and chronic under-treatment all have costs that ripple outward.

The good news: the conversation is shifting. More SF-based providers are specializing in perimenopause care, telehealth options are expanding, and women are increasingly sharing information with each other to fill the gaps that traditional medicine leaves behind.

The less good news: insurance coverage for HRT and related treatments remains a patchwork mess, and regulatory red tape continues to limit access to options that women in other countries take for granted.

Women's health shouldn't require a grassroots intelligence network to navigate. If San Francisco wants to call itself a progressive, health-forward city, it could start by making sure its healthcare infrastructure actually serves everyone — not just the demographics that medical research has historically prioritized.